Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2014. The report serves as a notification of transactions involving Persons Discharging Managerial Responsibility (PDMR) under the Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions related to executive compensation.
Material Changes
There are no material changes to the company's financial position or operations reported in this filing. The document details specific share sales and withholdings by PDMRs on February 13, 2014, to meet tax liabilities following the vesting of Performance Share Plan (PSP) awards granted in 2011.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It is a regulatory disclosure of specific share transactions.
Important Facts for Investors
- Transaction Date: February 13, 2014.
- Share Price: Ordinary Shares sold at £16.44; ADSs withheld at $54.81.
- Reason for Sale: To meet tax liabilities upon vesting of 2011 PSP awards.
- Ordinary Shares Sold:
- Mr. R Connor: 2,003 shares
- Mr. P Thomson: 3,229 shares
- Ms. E Walmsley: 35,866 shares
- Mrs. V Whyte: 3,229 shares
- ADSs Withheld:
- Mr. J Ford: 1,556 ADSs
- Notification Date: The Company and PDMRs were advised of these transactions on February 17, 2014.